AU Patent

AU2014261336A1 — Oral dosing of GLP-1 compounds

Assigned to Novo Nordisk AS · Expires 2015-10-08 · 11y expired

What this patent protects

The present invention relates to improved uses of GLP-1 peptides in oral therapy.

USPTO Abstract

The present invention relates to improved uses of GLP-1 peptides in oral therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014261336A1
Jurisdiction
AU
Classification
—
Expires
2015-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.